This biological shift means your body naturally tells you to stop eating sooner than it did before treatment
Findings Participants and Intervention: Between October 5, 2018, and February 1, 2019, 304 individuals were randomly assigned to either receive semaglutide 2.4 mg (n = 152) or placebo (n = 152) and were encompassed in the comprehensive analysis set (comprising all randomized individuals as per the intention-to-treat principle)
Whilst mild to moderate gastrointestinal symptoms are expected with Ozempic therapy, certain presentations warrant prompt medical assessment to exclude serious complications or conditions requiring intervention
Which symptoms require an ER visit
Which conditions call for careful evaluation before tirzepatide
Conclusion: Sema significantly reduced liver fat, which together with other findings, suggests a positive impact on disease activity and metabolic profile in a NAFLD population